Bayer has launched a Phase 4 clinical trial called REPLACE to evaluate Adempas (riociguat) in patients with pulmonary arterial hypertension (PAH)…
Articles by Joana Fernandes, PhD
Stem cells known as mesenchymal progenitor cells (MPCs) may contribute to the blood vessel anomalies causing pulmonary hypertension (PH), says a…
Antiphospholipid antibodies (aPL) could signal that a lupus patient is at risk of developing pulmonary hypertension (PH) and related conditions,…
The INOpulse portable oxygen provider widened blood vessels, lowered blood pressure and increased exercise capacity in pulmonary hypertension patients with idiopathic…
The prevalence of pregnant women with heart disease rose by 24 percent over a 10-year period, according to a study, “…
Eiger BioPharmaceuticals will host a lunch May 10 in New York City to discuss the need for potential new…
Selexipag improved the condition of Japanese with pulmonary arterial hypertension (PAH), according to a clinical trial. The United States and a…
Two U.S. companies, Respira Therapeutics and United Therapeutics, will jointly develop and license RT234 and its dry-powder inhaler drug delivery technology AOS-DPI to…
A significant proportion of patients with hyperthyroidism may have mild pulmonary hypertension (PH), according to the results of a recent…
Pulmonary hypertension (PH) may be triggered by therapies used in chronic myeloid leukemia (CML) treatment, namely the drugs Gleevec (imatinib), Tasigna…
Inhaled Revatio (sildenafil) appears to be superior to current oral forms of this approved pulmonary arterial hypertension (PAH) treatment by allowing for lower doses and potentially…
Screening patients with systemic sclerosis (SSc) for pulmonary arterial hypertension (PAH) may help identify patients with both conditions sooner to start appropriate…